Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 17, 2021 - Issue 2
Submit an article Journal homepage
326
Views
6
CrossRef citations to date
0
Altmetric
Review

An outlook on the trigeminovascular mechanisms of action and side effects concerns of some potential neuropeptidergic antimigraine therapies

Abimael González-Hernándeza Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, MéxicoCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6472-1419View further author information
ORCID Icon,
Miguel Condés-Laraa Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, MéxicoView further author information
,
Enrique García-Bolla Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, MéxicoView further author information
&
Carlos M. Villalónb Departamento de Farmacobiología, Cinvestav-Coapa, Ciudad de México, MéxicoCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4117-1343View further author information
ORCID Icon
Pages 179-199 | Received 15 Sep 2020, Accepted 23 Nov 2020, Published online: 20 Jan 2021

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Abimael González-Hernández, Bruno A. Marichal-Cancino & Carlos M. Villalón. (2021) The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events. Expert Opinion on Drug Metabolism & Toxicology 17:10, pages 1223-1235.
Read now
Bruno A. Marichal-Cancino, Abimael González-Hernández, Raquel Guerrero-Alba, Roberto Medina-Santillán & Carlos M. Villalón. (2021) A critical review of the neurovascular nature of migraine and the main mechanisms of action of prophylactic antimigraine medications. Expert Review of Neurotherapeutics 21:9, pages 1035-1050.
Read now
Qi Wang, Jingfang Liu, Hao Sun, YongFei Dong, WeiLiang Tan, Zaixiang Tang & YiGuo Jiang. Adverse event profile of CGRP monoclonal antibodies: findings from the FDA adverse event reporting database. Expert Opinion on Drug Safety 0:0, pages 1-11.
Read now

Articles from other publishers (3)

Anna K. Szewczyk, Samiye Ulutas, Tülin Aktürk, Linda Al-Hassany, Corinna Börner, Federica Cernigliaro, Michalis Kodounis, Salvatore Lo Cascio, David Mikolajek, Dilara Onan, Chiara Ragaglini, Susanna Ratti, Eduardo Rivera-Mancilla, Sofia Tsanoula, Rafael Villino, Karl Messlinger, Antoinette Maassen Van Den Brink & Tessa de Vries. (2023) Prolactin and oxytocin: potential targets for migraine treatment. The Journal of Headache and Pain 24:1.
Crossref
Eduardo Rivera-Mancilla & Antoinette MaassenVanDenBrink. 2022. Novel Synthetic Drugs in Migraine. Novel Synthetic Drugs in Migraine 1 17 .
Frederick G. Freitag. (2021) Headache Medicine Grand Challenge: Headache: A New Frontier, A New Challenge. Frontiers in Pain Research 2.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.